We are advancing a robust pipeline of bispecific antibody EpiTACs in high-need oncology and immunology indications.
EPI-326 is a tissue-selective bispecific antibody for EGFR-driven cancers that degrades wild-type and mutant EGFR in tumors. EPI-326 degrades EGFR independent to its form in tumors while sparing EGFR in healthy tissue. As a monotherapy and in combination with front-line standard of care therapies, EPI-326 has the potential to address significant unmet needs in multiple types of cancer, including mutant EGFR non-small cell lung cancer (NSCLC), wild-type EGFR head and neck squamous cell carcinoma (HNSCC), and colorectal cancer (CRC). It is currently being evaluated in a Phase 1 clinical trial in patients with NSCLC or HNSCC. To learn more about the trial, visit https://clinicaltrials.gov/study/NCT07462377
